CALCIPOTRIOL, (5E)-

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C27H40O3
Molecular Weight	412.6047
Optical Activity	UNSPECIFIED
Defined Stereocenters	7 / 7
E/Z Centers	3
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C3/C[C@@H](O)C[C@H](O)C3=C)[C@H](C)\C=C\[C@@H](O)C4CC4

InChI

InChIKey=LWQQLNNNIPYSNX-GMGGYIQASA-N

InChI=1S/C27H40O3/c1-17(6-13-25(29)20-8-9-20)23-11-12-24-19(5-4-14-27(23,24)3)7-10-21-15-22(28)16-26(30)18(21)2/h6-7,10,13,17,20,22-26,28-30H,2,4-5,8-9,11-12,14-16H2,1,3H3/b13-6+,19-7+,21-10+/t17-,22-,23-,24+,25-,26+,27-/m1/s1

HIDE SMILES / InChI

Description
Sources: https://www.drugs.com/dovonex.html | https://www.ncbi.nlm.nih.gov/pubmed/22879719 | http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020554s006lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/16880407https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=19941115&CC=JP&NR=H06316558A&KC=Ahttps://www.ncbi.nlm.nih.gov/pubmed/23777514

5E-Calcipotriol is a geometric analog of vitamin D derivative calcipotriol. It was shown to enhance anticancer activity of 5-fluorouracil in an in vivo mouse colon cancer model and anticancer activity of imatinib in an in vivo lung cancer model. The compound also demonstrated activity in a subcutaneous MCF-7 model of breast cancer in vivo. The detailed mechanism of action for 5E-calcipotriol is not known.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Vitamin D receptor 25 Target ID: CHEMBL1977 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16880407	Activator 1430

Conditions

Condition	Modality	Highest Phase	Product
Colon cancer 62 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23777514	Palliative	Preclinical	Unknown Approved Use Unknown
Lung cancer 69 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26580599	Palliative	Preclinical	Unknown Approved Use Unknown
Breast cancer 434 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24202449	Primary	Preclinical	Unknown Approved Use Unknown
Unknown 2578
Plaque psoriasis 16 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020554s006lbl.pdf	Curative	Approved 8429	DOVONEX Approved Use Calcipotriene Cream, 0.005%, is indicated for the treatment of plaque psoriasis. The safety and effectiveness of topical calcipotriene in dermatoses other than psoriasis have not been established. Launch Date 1993

C_max

Value	Dose	Co-administered	Analyte	Population
55.9 pg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207589s000lbl.pdf	0.005 % 1 times / day multiple, topical dose: 0.005 % route of administration: Topical experiment type: MULTIPLE co-administered: BETAMETHASONE DIPROPIONATE	BETAMETHASONE DIPROPIONATE	CALCIPOTRIENE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
24.4 pg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207589s000lbl.pdf	0.005 % 1 times / day multiple, topical dose: 0.005 % route of administration: Topical experiment type: MULTIPLE co-administered: BETAMETHASONE DIPROPIONATE	BETAMETHASONE DIPROPIONATE	MC1080 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
82.5 pg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207589s000lbl.pdf	0.005 % 1 times / day multiple, topical dose: 0.005 % route of administration: Topical experiment type: MULTIPLE co-administered: BETAMETHASONE DIPROPIONATE	BETAMETHASONE DIPROPIONATE	CALCIPOTRIENE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
59.3 pg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207589s000lbl.pdf	0.005 % 1 times / day multiple, topical dose: 0.005 % route of administration: Topical experiment type: MULTIPLE co-administered: BETAMETHASONE DIPROPIONATE	BETAMETHASONE DIPROPIONATE	MC1080 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
0.005 % 2 times / day multiple, topical Recommended Dose: 0.005 %, 2 times / day Route: topical Route: multiple Dose: 0.005 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022563Orig1s000MedR.pdf	unhealthy, 48 n = 473 Health Status: unhealthy Condition: psoriasis Age Group: 48 Sex: M+F Population Size: 473 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022563Orig1s000MedR.pdf	Disc. AE: Application site bleeding, Application site erythema... Other AEs: Dental caries, Hypersensitivity... AEs leading to discontinuation/dose reduction: Application site bleeding (1 patient) Application site erythema (6 patients) Application site exfoliation (1 patient) Application site irritation (5 patients) Application site pruritus (6 patients) Application site swelling (1 patient) Application site folliculitis (1 patient) Other AEs: Dental caries (1 patient) Hypersensitivity (1 patient) Musculoskeletal pain (1 patient) Migraine (1 patient) Atrial fibrillation (1 patient) Cardiac failure congestive (1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022563Orig1s000MedR.pdf
0.005 % 2 times / day multiple, topical Recommended Dose: 0.005 %, 2 times / day Route: topical Route: multiple Dose: 0.005 %, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/22587791/	unhealthy, 48.2 n = 437 Health Status: unhealthy Condition: psoriasis Age Group: 48.2 Sex: M+F Population Size: 437 Sources: https://pubmed.ncbi.nlm.nih.gov/22587791/	Disc. AE: Application site erythema, Application site irritation... Other AEs: Nausea, Toothache... AEs leading to discontinuation/dose reduction: Application site erythema (9 patients) Application site irritation (9 patients) Application site pruritus (7 patients) Other AEs: Nausea (1 patient) Toothache (2 patients) Nasopharyngitis (7 patients) Upper respiratory tract infection (2 patients) Headache (3 patients) Cough (1 patient) Hypertension (2 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/22587791/

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
MRP1 106 P-gp 1461 BCRP 699

Drug as perpetrator

Target	Modality	Activity
BCRP 773	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/30232176/	yes [IC50 20.8 uM]
P-gp 1650	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/30232176/	yes [IC50 37.9 uM]
MRP1 172	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/30232176/	yes [IC50 6 uM]

Sourcing

Vendor/Aggregator	ID	URL
AA Blocks	AA007RGL	https://www.aablocks.com/goods/Goods/detail?id=AA007RGL
AHH Chemical co.,ltd	MT-01143	http://www.ahhchemical.com/product/MT-01143.html
AK Scientific, Inc. (AKSCI)	O763	http://www.aksci.com/item_detail.php?cat=O763
Aaron Chemicals	AR007S8D	http://www.aaronchem.com/112965-21-6
Achemtek	0104-005732	http://www.achemtek.com/112828-00-9
Acorn PharmaTech	ACN-032164	http://www.acornpharmatech.com/
Aurum Pharmatech LLC	W-5148	http://www.Aurumpharmatech.com/Product/ProductDetails/W_5148
AvaChem Scientific	2206	http://www.avachem.com/productSearch.asp?2206
Capot Chemical	18810	http://www.capotchem.com/en/18810.htm
Capot Chemical	PubChem18810	http://www.capotchem.com/en/18810.htm
Capot Chemical	19334	http://www.capotchem.com/en/19334.htm
Capot Chemical	PubChem19334	http://www.capotchem.com/en/19334.htm
Chem Scene	CS-0387	http://www.chemscene.com/112965-21-6.html
ChemMol	97900692	http://www.chemmol.com/chemmol/97900692.html
Chemspace	CSSB00020656683	https://chem-space.com/CSSB00020656683
Clearsynth	CS-O-06254	https://www.clearsynth.com/en/CSO06254.html
Excenen	EX-A4430	https://www.excenen.com/searchresultlist.php?id=EX-A4430
Glentham Life Sciences	GP2043	http://www.glentham.com/products/product/GP2043/
Lab Network	LN01343326	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01343326
MedChem Express	HY-10001	https://www.medchemexpress.com/Calcipotriol.html
OChem	7044	http://www.ocheminc.com/index.php?act=psearch&pid=828C009
Selleck Chemicals	S3739	http://www.selleckchem.com/products/calcipotriene.html
Smolecule	S800532	https://www.smolecule.com/products/s800532
Tocris	2700	https://www.tocris.com/products/calcipotriol_2700
eNovation Chemicals	D371144	https://www.enovationchem.com/ProductDetails.asp?ProductID=D371144
eNovation Chemicals	D675441	https://www.enovationchem.com/ProductDetails.asp?ProductID=D675441
eNovation Chemicals	D761746	https://www.enovationchem.com/ProductDetails.asp?ProductID=D761746
eNovation Chemicals	Y0975952	https://www.enovationchem.com/ProductDetails.asp?ProductID=Y0975952
iChemical	EBD7189	http://www.ichemical.com/products/112828-00-9.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs

PubMed

Title	Date	PubMed
Effects of 1 alpha,25-dihydroxy-vitamin D3 and calcipotriol on organotypic cultures of outer root sheath cells: a potential model to evaluate antipsoriatic drugs.	1993	7508215
Hypercalcaemia associated with calcipotriol (Dovonex) treatment.	1993 Apr 3	8490416
Profile of ligand specificity of the vitamin D binding protein for 1 alpha,25-dihydroxyvitamin D3 and its analogs.	1994 Aug	7976510
Calcipotriol inhibits rectal epithelial cell proliferation in ulcerative proctocolitis.	1994 Dec	7829008
Hypercalcaemia during treatment of psoriasis with calcipotriol.	1994 Jun	8011511
Hypercalcaemic crisis after excessive topical use of a vitamin D derivative.	1994 Mar	8120527
Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.	1995 Jan	7530193
Cytotoxic effects of 1 alpha,25-dihydroxyvitamin D3 and synthetic vitamin D3 analogues on a glioma cell line.	1996 Feb 27	8620449
Topical calcipotriene has no short-term effect on calcium and bone metabolism of patients with psoriasis.	1996 Mar	8609254
The use of topical calcipotriene/calcipotriol in conditions other than plaque-type psoriasis.	1997 Sep	9344189
Nonpsoriatic uses of calcipotriol.	2002 Sep-Oct	12196891
Severe hypercalcemia and hypernatremia associated with calcipotriol for treatment of psoriasis.	2004	14999528
Prediction of genotoxicity of chemical compounds by statistical learning methods.	2005 Jun	15962942
Vitamin D receptor gene polymorphisms, particularly the novel A-1012G promoter polymorphism, are associated with vitamin D3 responsiveness and non-familial susceptibility in psoriasis.	2005 May	15864137
Topical vitamin D3 and low-calcemic analogs induce thymic stromal lymphopoietin in mouse keratinocytes and trigger an atopic dermatitis.	2006 Aug 1	16880407
Effect of topical vitamin D analogue on in vivo contact sensitization.	2006 Oct	17043189
Hypercalcemia caused by vitamin D3 analogs in psoriasis treatment.	2007 Dec	18173537
Calcipotriol induces autophagy in HeLa cells and keratinocytes.	2011 Apr	21228817
The atopic dermatitis-like symptoms induced by MC903 were alleviated in JNK1 knockout mice.	2013 Dec	24046278
Vitamin D analogs enhance the anticancer activity of 5-fluorouracil in an in vivo mouse colon cancer model.	2013 Jun 18	23777514
Synthesis and Biological Activity of Diastereomeric and Geometric Analogs of Calcipotriol, PRI-2202 and PRI-2205, Against Human HL-60 Leukemia and MCF-7 Breast Cancer Cells.	2013 Oct 31	24202449
Synergistic induction of human cathelicidin antimicrobial peptide gene expression by vitamin D and stilbenoids.	2014 Mar	24039193
Vitamin D Analogs Potentiate the Antitumor Effect of Imatinib Mesylate in a Human A549 Lung Tumor Model.	2015 Nov 13	26580599

Patents

Sample Use Guides

In Vivo Use Guide

Apply a thin layer of Dovonex Cream to the affected skin twice daily and rub in gently and completely. The safety and efficacy of Dovonex Cream have been demonstrated in patients treated for eight weeks.

Route of Administration: Topical

In Vitro Use Guide

The immune modulatory effects of betamethasone, calcipotriol and the combination in ex vivo cultures of psoriatic skin and in vitro cultures of primary human cells that recapitulate key cellular activities of psoriatic inflammation were investigated and compared.

Name

Type

Language

CALCIPOTRIOL, (5E)-

Common Name

English

PRI 2205

Code

English

CALCIPOTRIENE RELATED COMPOUND C [USP IMPURITY]

Common Name

English

9,10-SECOCHOLA-5,7,10(19),22-TETRAENE-1,3,24-TRIOL, 24-CYCLOPROPYL-, (1.ALPHA.,3.BETA.,5E,7E,22E,24S)-

Common Name

English

CALCIPOTRIENE RELATED COMPOUND C [USP-RS]

Common Name

English

1,3-CYCLOHEXANEDIOL, 5-((2E)-2-((1R,3AS,7AR)-1-((1R,2E,4S)-4-CYCLOPROPYL-4-HYDROXY-1-METHYL-2-BUTEN-1-YL)OCTAHYDRO-7A-METHYL-4H-INDEN-4-YLIDENE)ETHYLIDENE)-4-METHYLENE-, (1S,3S,5E)-

Common Name

English

(5E)-CALCIPOTRIOL

Common Name

English

PRI-2205

Code

English

5,6-TRANS-CALCIPOTRIOL

Common Name

English

(5E)-CALCIPOTRIENE

Common Name

English

CALCIPOTRIOL IMPURITY C [EP IMPURITY]

Common Name

English

(5E,7E,22E,24S)-24-CYCLOPROPYL-9,10-SECOCHOLA-5,7,10(19),22-TETRAENE-1.ALPHA.,3.BETA.,24-TRIOL

Common Name

English

CALCIPOTRIOL MONOHYDRATE IMPURITY C [EP IMPURITY]

Common Name

English

Code System Code Type Description

PUBCHEM

9801803

Created by admin on Sat Dec 16 01:39:52 GMT 2023 , Edited by admin on Sat Dec 16 01:39:52 GMT 2023

PRIMARY

FDA UNII

QRA3492A7Q

Created by admin on Sat Dec 16 01:39:52 GMT 2023 , Edited by admin on Sat Dec 16 01:39:52 GMT 2023

PRIMARY

CAS

113082-99-8

Created by admin on Sat Dec 16 01:39:52 GMT 2023 , Edited by admin on Sat Dec 16 01:39:52 GMT 2023

PRIMARY

RS_ITEM_NUM

1086152

Created by admin on Sat Dec 16 01:39:52 GMT 2023 , Edited by admin on Sat Dec 16 01:39:52 GMT 2023

PRIMARY

SUBSTANCE RECORD


					QRA3492A7Q

CALCIPOTRIOL, (5E)-

AE	Significance	Dose	Population
Atrial fibrillation	1 patient	0.005 % 2 times / day multiple, topical Recommended Dose: 0.005 %, 2 times / day Route: topical Route: multiple Dose: 0.005 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022563Orig1s000MedR.pdf	unhealthy, 48 n = 473 Health Status: unhealthy Condition: psoriasis Age Group: 48 Sex: M+F Population Size: 473 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022563Orig1s000MedR.pdf
Cardiac failure congestive	1 patient	0.005 % 2 times / day multiple, topical Recommended Dose: 0.005 %, 2 times / day Route: topical Route: multiple Dose: 0.005 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022563Orig1s000MedR.pdf	unhealthy, 48 n = 473 Health Status: unhealthy Condition: psoriasis Age Group: 48 Sex: M+F Population Size: 473 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022563Orig1s000MedR.pdf
Dental caries	1 patient	0.005 % 2 times / day multiple, topical Recommended Dose: 0.005 %, 2 times / day Route: topical Route: multiple Dose: 0.005 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022563Orig1s000MedR.pdf	unhealthy, 48 n = 473 Health Status: unhealthy Condition: psoriasis Age Group: 48 Sex: M+F Population Size: 473 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022563Orig1s000MedR.pdf
Hypersensitivity	1 patient	0.005 % 2 times / day multiple, topical Recommended Dose: 0.005 %, 2 times / day Route: topical Route: multiple Dose: 0.005 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022563Orig1s000MedR.pdf	unhealthy, 48 n = 473 Health Status: unhealthy Condition: psoriasis Age Group: 48 Sex: M+F Population Size: 473 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022563Orig1s000MedR.pdf
Migraine	1 patient	0.005 % 2 times / day multiple, topical Recommended Dose: 0.005 %, 2 times / day Route: topical Route: multiple Dose: 0.005 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022563Orig1s000MedR.pdf	unhealthy, 48 n = 473 Health Status: unhealthy Condition: psoriasis Age Group: 48 Sex: M+F Population Size: 473 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022563Orig1s000MedR.pdf
Musculoskeletal pain	1 patient	0.005 % 2 times / day multiple, topical Recommended Dose: 0.005 %, 2 times / day Route: topical Route: multiple Dose: 0.005 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022563Orig1s000MedR.pdf	unhealthy, 48 n = 473 Health Status: unhealthy Condition: psoriasis Age Group: 48 Sex: M+F Population Size: 473 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022563Orig1s000MedR.pdf
Application site bleeding	1 patient Disc. AE	0.005 % 2 times / day multiple, topical Recommended Dose: 0.005 %, 2 times / day Route: topical Route: multiple Dose: 0.005 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022563Orig1s000MedR.pdf	unhealthy, 48 n = 473 Health Status: unhealthy Condition: psoriasis Age Group: 48 Sex: M+F Population Size: 473 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022563Orig1s000MedR.pdf
Application site exfoliation	1 patient Disc. AE	0.005 % 2 times / day multiple, topical Recommended Dose: 0.005 %, 2 times / day Route: topical Route: multiple Dose: 0.005 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022563Orig1s000MedR.pdf	unhealthy, 48 n = 473 Health Status: unhealthy Condition: psoriasis Age Group: 48 Sex: M+F Population Size: 473 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022563Orig1s000MedR.pdf
Application site folliculitis	1 patient Disc. AE	0.005 % 2 times / day multiple, topical Recommended Dose: 0.005 %, 2 times / day Route: topical Route: multiple Dose: 0.005 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022563Orig1s000MedR.pdf	unhealthy, 48 n = 473 Health Status: unhealthy Condition: psoriasis Age Group: 48 Sex: M+F Population Size: 473 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022563Orig1s000MedR.pdf
Application site swelling	1 patient Disc. AE	0.005 % 2 times / day multiple, topical Recommended Dose: 0.005 %, 2 times / day Route: topical Route: multiple Dose: 0.005 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022563Orig1s000MedR.pdf	unhealthy, 48 n = 473 Health Status: unhealthy Condition: psoriasis Age Group: 48 Sex: M+F Population Size: 473 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022563Orig1s000MedR.pdf
Application site irritation	5 patients Disc. AE	0.005 % 2 times / day multiple, topical Recommended Dose: 0.005 %, 2 times / day Route: topical Route: multiple Dose: 0.005 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022563Orig1s000MedR.pdf	unhealthy, 48 n = 473 Health Status: unhealthy Condition: psoriasis Age Group: 48 Sex: M+F Population Size: 473 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022563Orig1s000MedR.pdf
Application site erythema	6 patients Disc. AE	0.005 % 2 times / day multiple, topical Recommended Dose: 0.005 %, 2 times / day Route: topical Route: multiple Dose: 0.005 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022563Orig1s000MedR.pdf	unhealthy, 48 n = 473 Health Status: unhealthy Condition: psoriasis Age Group: 48 Sex: M+F Population Size: 473 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022563Orig1s000MedR.pdf
Application site pruritus	6 patients Disc. AE	0.005 % 2 times / day multiple, topical Recommended Dose: 0.005 %, 2 times / day Route: topical Route: multiple Dose: 0.005 %, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022563Orig1s000MedR.pdf	unhealthy, 48 n = 473 Health Status: unhealthy Condition: psoriasis Age Group: 48 Sex: M+F Population Size: 473 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022563Orig1s000MedR.pdf
Cough	1 patient	0.005 % 2 times / day multiple, topical Recommended Dose: 0.005 %, 2 times / day Route: topical Route: multiple Dose: 0.005 %, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/22587791/	unhealthy, 48.2 n = 437 Health Status: unhealthy Condition: psoriasis Age Group: 48.2 Sex: M+F Population Size: 437 Sources: https://pubmed.ncbi.nlm.nih.gov/22587791/
Nausea	1 patient	0.005 % 2 times / day multiple, topical Recommended Dose: 0.005 %, 2 times / day Route: topical Route: multiple Dose: 0.005 %, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/22587791/	unhealthy, 48.2 n = 437 Health Status: unhealthy Condition: psoriasis Age Group: 48.2 Sex: M+F Population Size: 437 Sources: https://pubmed.ncbi.nlm.nih.gov/22587791/
Hypertension	2 patients	0.005 % 2 times / day multiple, topical Recommended Dose: 0.005 %, 2 times / day Route: topical Route: multiple Dose: 0.005 %, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/22587791/	unhealthy, 48.2 n = 437 Health Status: unhealthy Condition: psoriasis Age Group: 48.2 Sex: M+F Population Size: 437 Sources: https://pubmed.ncbi.nlm.nih.gov/22587791/
Toothache	2 patients	0.005 % 2 times / day multiple, topical Recommended Dose: 0.005 %, 2 times / day Route: topical Route: multiple Dose: 0.005 %, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/22587791/	unhealthy, 48.2 n = 437 Health Status: unhealthy Condition: psoriasis Age Group: 48.2 Sex: M+F Population Size: 437 Sources: https://pubmed.ncbi.nlm.nih.gov/22587791/
Upper respiratory tract infection	2 patients	0.005 % 2 times / day multiple, topical Recommended Dose: 0.005 %, 2 times / day Route: topical Route: multiple Dose: 0.005 %, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/22587791/	unhealthy, 48.2 n = 437 Health Status: unhealthy Condition: psoriasis Age Group: 48.2 Sex: M+F Population Size: 437 Sources: https://pubmed.ncbi.nlm.nih.gov/22587791/
Headache	3 patients	0.005 % 2 times / day multiple, topical Recommended Dose: 0.005 %, 2 times / day Route: topical Route: multiple Dose: 0.005 %, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/22587791/	unhealthy, 48.2 n = 437 Health Status: unhealthy Condition: psoriasis Age Group: 48.2 Sex: M+F Population Size: 437 Sources: https://pubmed.ncbi.nlm.nih.gov/22587791/
Nasopharyngitis	7 patients	0.005 % 2 times / day multiple, topical Recommended Dose: 0.005 %, 2 times / day Route: topical Route: multiple Dose: 0.005 %, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/22587791/	unhealthy, 48.2 n = 437 Health Status: unhealthy Condition: psoriasis Age Group: 48.2 Sex: M+F Population Size: 437 Sources: https://pubmed.ncbi.nlm.nih.gov/22587791/
Application site pruritus	7 patients Disc. AE	0.005 % 2 times / day multiple, topical Recommended Dose: 0.005 %, 2 times / day Route: topical Route: multiple Dose: 0.005 %, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/22587791/	unhealthy, 48.2 n = 437 Health Status: unhealthy Condition: psoriasis Age Group: 48.2 Sex: M+F Population Size: 437 Sources: https://pubmed.ncbi.nlm.nih.gov/22587791/
Application site erythema	9 patients Disc. AE	0.005 % 2 times / day multiple, topical Recommended Dose: 0.005 %, 2 times / day Route: topical Route: multiple Dose: 0.005 %, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/22587791/	unhealthy, 48.2 n = 437 Health Status: unhealthy Condition: psoriasis Age Group: 48.2 Sex: M+F Population Size: 437 Sources: https://pubmed.ncbi.nlm.nih.gov/22587791/
Application site irritation	9 patients Disc. AE	0.005 % 2 times / day multiple, topical Recommended Dose: 0.005 %, 2 times / day Route: topical Route: multiple Dose: 0.005 %, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/22587791/	unhealthy, 48.2 n = 437 Health Status: unhealthy Condition: psoriasis Age Group: 48.2 Sex: M+F Population Size: 437 Sources: https://pubmed.ncbi.nlm.nih.gov/22587791/

Details

SMILES

InChI

Originator

Approval Year

Targets

Conditions

Approved Use

Approved Use

Approved Use

Approved Use

Launch Date

Cmax

AUC

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Sourcing

PubMed

Patents

Sample Use Guides

C_max

Drug as perpetrator